Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

BioLineRx (BLRX) EBITDA: 2012-2024

Historic EBITDA for BioLineRx (BLRX) over the last 13 years, with Dec 2024 value amounting to -$20.4 million.

  • BioLineRx's EBITDA rose 714.05% to $3.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$746,000, marking a year-over-year increase of 97.60%. This contributed to the annual value of -$20.4 million for FY2024, which is 58.93% up from last year.
  • Latest data reveals that BioLineRx reported EBITDA of -$20.4 million as of FY2024, which was up 58.93% from -$49.7 million recorded in FY2023.
  • In the past 5 years, BioLineRx's EBITDA registered a high of -$20.4 million during FY2024, and its lowest value of -$49.7 million during FY2023.
  • Over the past 3 years, BioLineRx's median EBITDA value was -$29.2 million (recorded in 2022), while the average stood at -$33.1 million.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 70.44% in 2023, then skyrocketed by 58.93% in 2024.
  • Over the past 5 years, BioLineRx's EBITDA (Yearly) stood at -$22.9 million in 2020, then dropped by 8.07% to -$24.8 million in 2021, then dropped by 17.68% to -$29.2 million in 2022, then slumped by 70.44% to -$49.7 million in 2023, then spiked by 58.93% to -$20.4 million in 2024.